[Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma].
Thirty-three patients with malignant melanoma and regional lymph node metastases who underwent lymph node dissection were additionally given polychemotherapy with carmustine, hydroxycarbamide and dacarbazine immediately before surgery and up to five times postoperatively. Twenty-nine patients were only treated surgically. These two groups were comparable as regards prognostic criteria, in particular tumour size, ulceration and the number of lymph nodes affected, although the individual follow-up periods varied considerably. The group given chemotherapy showed better results than the control group undergoing surgery alone. The log rank test yielded a significant difference (P less than 0.05) with respect to the probability of relapse-free survival but not as regards probability of survival time. Patients with ulcerated primary melanomas and with a large number of affected lymph nodes had a less favourable prognosis. The major side effects of chemotherapy were transient nausea and bone marrow depression.
B M
BM
Czarnetzki
V
V
Aragon
E B
EB
Bröcker
V
V
Krieg
H
H
Bünte
E
E
Macher
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007264:Inguinal Canal / Q000601:surgery; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008545:Melanoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis
D003606:Dacarbazine; D002330:Carmustine; D006918:Hydroxyurea
Adjuvante Polychemotherapie zusätzlich zur radikalen operativen Behandlung regionaler Lymphknotenmetastasen beim malignen Melanom.